MAINZ BIOMED N.V. 8-K

What Happened Mainz Biomed N.V. filed an 8-K on March 11, 2026 announcing that Robert P. Liscouski was appointed to the company’s board of directors as Chairman of the Board. His director term runs until the Company’s extraordinary general meeting currently planned for April 2026 (or until a successor is elected). The filing also discloses a Nasdaq ticker symbol change: the company will cease trading under “MYNZ” and begin trading under “QUCY.” A press release dated March 11, 2026 was furnished as Exhibit 99.1.

Key Details

• Appointment: Robert P. Liscouski named Chairman of the Board, effective March 11, 2026.
• Director term: Expires at the extraordinary general meeting currently planned for April 2026, or upon successor election/resignation/removal.
• Ticker change: Trading will move from “MYNZ” to “QUCY” on the Nasdaq; the change does not affect security holder rights.
• CUSIP: No change to the Company’s CUSIP. Company reports no family relationships or reportable related-party transactions involving Mr. Liscouski.

Why It Matters A new board chair can influence corporate governance, strategic oversight, and investor relations, so the appointment is material governance news for shareholders. The Nasdaq ticker change (MYNZ → QUCY) is an administrative update investors should note for trading and portfolio tracking; it does not change shareholder rights or the company’s CUSIP. The filing contains no disclosed related-party transactions tied to the appointment.